advanced search

RESPIRATORY

QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC FORMULATIONS
INDUSTRIALISATION
Jose Luis Encinas
Qualicaps
QUALI-V EXTRA DRY: A NOVEL CAPSULE FOR DELIVERING HYGROSCOPIC FORMULATIONS
Jose Luis Encinas and Susana Ecenarro explore how the use of Quali-V® Extra Dry capsules can help improve product stability and, crucially, lead to efficiencies and savings in drug product manufacture.
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
INDUSTRIALISATION
Steve Wardell
AUTOMATING PREVIOUSLY IMPOSSIBLE MANUAL INSPECTIONS USING MACHINE LEARNING & CONCURRENT VALIDATION
Steve Wardell and Catherine Thacker explore how machine learning technology is enabling the automation of challenging, or previously impossible, manual inspections.
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
CONNECTIVITY
Eric Dessertenne
Biocorp
COMPLETING ITS TRANSITION FROM GENESIS TO MATURITY, BIOCORP OPENS NEW HORIZONS
As Biocorp prepares for the market launch of its connected injector pen add-on, Mallya, Eric Dessertenne and Arnaud Guillet share insights about key steps in the company’s development. The article discusses the many partnership Biocorp has entered in to, and includes a mini-interview with Sergio Monti, Plant Manager for one such partner, V.A.R.I.
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
CONNECTIVITY
Thierry Decock
Nemera
CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL
Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.
THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A NETWORK PERSPECTIVE
CONNECTIVITY
Dr Benjamin Jung
H&T Presspart
THE FUTURE OF CONNECTED ASTHMA AND COPD CARE: A NETWORK PERSPECTIVE
Benjamin Jung uses a network theory approach to look at the ongoing issue of adherence when it comes to the treatment of asthma and COPD, and the players involved in overcoming it.
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
CONNECTIVITY
Matt Jones
DCA
DON’T DEVELOP A CONNECTED DRUG DELIVERY DEVICE WITHOUT READING THIS
Matt Jones summarises some of the key challenges and opportunities in the development of connected drug delivery devices, focusing in detail on deciding what a connected drug delivery device should do, designing for a coin cell, direct cellular connection and antenna design.
USER-CENTRED DEVICE CONNECTIVITY
EXPERT VIEW
Mark Tunkel
USER-CENTRED DEVICE CONNECTIVITY
Mark Tunkel and Carolyn Rose discuss the benefits of taking a user-needs approach, and mapping the patient journey, in a connectivity strategy.
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
CONNECTIVITY
Neil Williams
Phillips Medisize
LOW-COST CONNECTIVITY MEETS PATIENT & PHARMA MEDICATION MANAGEMENT NEEDS
Neil Williams describes the potential connected drug delivery systems hold to address serious challenges in healthcare, including poor adherence, and also deliver substantial value, and outlines the company’s highly scalable enterprise platform, the Connected Health Platform.
BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE
RESPIRATORY
Joe Reynolds
Noble
BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE
Joe Reynolds discusses the current state of pulmonary drug delivery device trainers, including their value to patients, the complexities of modern design and the stringent quality requirements.
AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES
EXPERT VIEW
Simon Drexler
AUTOMATING UNDER UNCERTAINTY – GOOD PRACTICES
Simon Drexler discusses lessons learned and good practices when dealing with uncertainty at the various stages of automation development for drug delivery device manufacturing.
GUILLAUME BROUET, APTAR PHARMA
INTERVIEW
Guillaume Brouet
Aptar Pharma
GUILLAUME BROUET, APTAR PHARMA
Guillaume Brouet talks with ONdrugDelivery Magazine about how Aptar Pharma uses its device development expertise and infrastructure to provide its pharmaceutical company customers a comprehensive services offering around device development, global regulatory approval and commercialisation.
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
EXPERT VIEW
David Belton
THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT
David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.
PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP
INTERVIEW
Paul Allsop
Bespak
PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP
Consort Medical's Paul Allsop, Miles Kottman, Hannah Priestly and Jon Reed talk with ONdrugDelivery Magazine about the company’s integrated formulation and device offering, and focus on its simple, low-cost, single unit-dose, spring powered nasal device, Unidose Xtra.
130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC
NASAL
Dr Todd Pizitz
130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC
Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
EXPERT VIEW
Dr Igor Gonda
IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?
Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.
DEPOSITION IN THREE NASAL CAST MODELS USING RETRONOSE CONCEPT
RESPIRATORY
Dr Laurent Vecellio
DEPOSITION IN THREE NASAL CAST MODELS USING RETRONOSE CONCEPT
Laurent Vecellio, Déborah Le Pennec, Guillaume Grevin and Alain Regard discuss a study conducted to test particle deposition characteristics of the RetroNose device prototype for nasal drug delivery.
2019 ISAM CONGRESS PREVIEW
CONFERENCE SHOWCASE
Dr Barbara Rothen-Rutishauser
2019 ISAM CONGRESS PREVIEW
Prof Dr Barbara Rothen-Rutishause previews the 22nd Congress of the International Society for Aerosols in Medicine (ISAM), which will be held in Montreux, Switzerland, from May 25-29, 2019.
SUCCESSFUL CONNECTED DEVICE DEVELOPMENT REQUIRES A ROBUST VALUE PROPOSITION
CONNECTIVITY
Eric Dessertenne
Biocorp
SUCCESSFUL CONNECTED DEVICE DEVELOPMENT REQUIRES A ROBUST VALUE PROPOSITION
Eric Dessertenn discusses the current status of connectivity in healthcare, its future, benefits both in terms of addressing adherence and big data analysis, and emphasises the need for a robust business case.
CAPMEDIC™: SIMPLIFYING INHALERS FOR REGULAR AND CORRECT USE
CONNECTIVITY
Dr Rajoshi Biswas
CAPMEDIC™: SIMPLIFYING INHALERS FOR REGULAR AND CORRECT USE
Rajoshi Biswa discusses the CapMedic device, which transforms a typical metered dose inhaler into a more user-friendly, efficacious delivery system.
FLOW MEASUREMENT IN SMART INHALERS FOR CONNECTED DRUG DELIVERY
CONNECTIVITY
Dr Andreas Alt
Sensirion
FLOW MEASUREMENT IN SMART INHALERS FOR CONNECTED DRUG DELIVERY
Andreas Alt discusses the value of adding sensor technology to inhalers by means of an add-on device, both to help patients track and manage their disease, and to improve compliance by providing feedback on inhalation technique.
WE’RE OFF TO SEE THE WIZARD: “USE-LIKE” PROTOTYPING OF DIGITAL CONCEPTS
EXPERT VIEW
Tom Lawrie-Fussey
WE’RE OFF TO SEE THE WIZARD: “USE-LIKE” PROTOTYPING OF DIGITAL CONCEPTS
Tom Lawrie-Fussey and Lucy Sheldon introduce “Wizard of Oz” testing, named after the classic novel and film, whereby experimenters can field test concepts at a very early stage by giving the illusion of a finished product, saving potential costly and time-consuming changes further along the development process.
NEBULISERS: TIME TO REINVENT THE WHEEL
EXPERT VIEW
Dr John N Pritchard
NEBULISERS: TIME TO REINVENT THE WHEEL
John Pritchard discusses the history of the nebuliser, its fall in popularity with the advent of DPIs and pMDIs, and its current resurgence due to the success of the mesh nebuliser, continuing on to how changing the development paradigm to utilise nebuliser technology more effectively can have significant benefits.
INHALABLE THERAPEUTIC BIOLOGICS, A PARADIGM SHIFT FOR NON-INVASIVE EFFICIENT MEDICAL TREATMENTS
PULMONARY
Susana Ecenarro
INHALABLE THERAPEUTIC BIOLOGICS, A PARADIGM SHIFT FOR NON-INVASIVE EFFICIENT MEDICAL TREATMENTS
Susana Ecenarro Probst and Francesca Buttini discuss the rising prominence of biologics in the pharmaceuticals market and how dry powder inhalers utilising hard capsules are a promising potential delivery method for these new drugs.
CITRUS FRUITS INSPIRE THE NEXT GENERATION OF AIRBORNE DRUG DELIVERY
EARLY INSIGHT
Dr Andrew K Dickerson
Fluids and Structures (FaST) Laboratory
CITRUS FRUITS INSPIRE THE NEXT GENERATION OF AIRBORNE DRUG DELIVERY
Andrew Dickerson discusses recent research undertaken by his team into the mechanics of liquid microjets created naturally by citrus fruits, and how they could be the key to a new design of drug delivery device.
Top